In human HCC cell lines, treatment with TGF-β inhibitor LY2109761 stops migration and invasion by upregulating E-cadherin [120], inhibits neo-angiogenesis, reduces tumor growth and metastasis of HCC cells by inhibiting CAFs proliferation [121]. This evidence concerns the gene CDH1 and neoplasm.